In reply: The cardiovascular risk associated with white coat hypertension itself is quite separate from the risk of treating white coat hypertension inappropriately.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Manios ED, Koroboki EA, Tsivgoulis GK, et al. Factors influencing white-coat effect. Am J Hypertens 2008; 21: 153-158.
- 2. Ejaz AA, Kazory A, Heinig ME. 24-hour blood pressure monitoring in the evaluation of supine hypertension and orthostatic hypotension. J Clin Hypertens (Greenwich) 2007; 9: 952-955.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
This letter has been prepared by members of the Ambulatory Blood Pressure Monitoring Consensus Committee of the National Heart Foundation and the High Blood Pressure Research Council of Australia.
Relevant disclosures provided in our original article (Med J Aust 2012; 197: 143-144; doi: 10.5694/mja11.11637).